ASP-7317
- Generic Name
- ASP-7317
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
ASP-7317 consists of human embryonic stem cell-derived retinal pigment epithelium cells.
- Associated Conditions
- -
- Associated Therapies
- -
Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Institute for Regenerative Medicine
- Target Recruit Count
- 11
- Registration Number
- NCT02463344
- Locations
- ๐บ๐ธ
Mass Eye and Ear, Boston, Massachusetts, United States
๐บ๐ธJules Stein Eye Institute, UCLA School of Medicine, Los Angeles, California, United States
๐บ๐ธBascom Palmer Eye Institute, Miami, Florida, United States
Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients
- First Posted Date
- 2015-05-15
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Institute for Regenerative Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT02445612
- Locations
- ๐บ๐ธ
Wills Eye Institute-Mid Atlantic Retina, Philadelphia, Pennsylvania, United States
๐บ๐ธJules Stein Eye Institute, UCLA School of Medicine, Los Angeles, California, United States
๐บ๐ธBascom Palmer Eye Institute, Miami, Florida, United States
Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Institute for Regenerative Medicine
- Target Recruit Count
- 12
- Registration Number
- NCT01469832
- Locations
- ๐ฌ๐ง
Lothian Health Board Headquarters at Waverley Gate, Edinburgh, United Kingdom
๐ฌ๐งMoorefields Eye Hospital NHS Foundation Trust, London, United Kingdom
๐ฌ๐งNewcastle on Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Institute for Regenerative Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT01344993
- Locations
- ๐บ๐ธ
Bascom Palmer Eye Institute, Miami, Florida, United States
๐บ๐ธJules Stein Eye Institute, UCLA School of Medicine, Los Angeles, California, United States
๐บ๐ธMass Eye and Ear, Boston, Massachusetts, United States
Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Institute for Regenerative Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT01345006
- Locations
- ๐บ๐ธ
Bascom Palmer Eye institute, Miami, Florida, United States
๐บ๐ธJules Stein Eye Institute, UCLA School of Medicine, Los Angeles, California, United States
๐บ๐ธWills Eye Institute-Mid Atlantic Retina, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.